Immunocore's CEO and Head of R&D discuss the company's PRAME data at #ASCO24
Bahija Jallal and David Berman go over Immunocore's PRAME data in cutaneous melanoma and explain why they believe that the disease control rate they are seeing today could translate into a robust OS number in the future.